A novel stop-gain NF1 variant in neurofibromatosis type 1 and bilateral optic atrophy without optic gliomas

References

• Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124–33. doi:10.1542/peds.2007-3204.
   PubMed Web of Science ®Google Scholar
• Kinori M, Hodgson N, Zeid JL. Ophthalmic manifestations in neurofibromatosis type 1. Surv Ophthalmol. 2018;63:518–33. doi:10.1016/j.survophthal.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Cassina M, Frizziero L, Opocher E, Parrozzani R, Sorrentino U, Viscardi E, Miglionico G, Midena E, Clementi M, Trevisson E. Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations. Cancers Basel. 2019;11:1790. doi:10.3390/cancers11111790.
   PubMed Web of Science ®Google Scholar
• Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181–6.
   PubMed Web of Science ®Google Scholar
• Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89:1–6. doi:10.1002/(SICI)1096-8628(19990326)89:1<1:AID-AJMG3>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Brodsky MC. Optic atrophy in children. In: Brodsky MC, editor. Pediatric neuro-ophthalmology. New York, (NY): Springer, 2016;pp. 199–274. doi:10.1007/978-1-4939-3384-6_4.
   Google Scholar
• Maeda-Katahira A, Nakamura N, Hayashi T, Katagiri S, Shimizu S, Ohde H, Matsunaga T, Kaga K, Nakano T, Kameya S, et al. Autosomal dominant optic atrophy with OPA1 gene mutations accompanied by auditory neuropathy and other systemic complications in a Japanese cohort. Mol Vis. 2019;25:559–73.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Gekka T, Omoto S, Takeuchi T, Kitahara K. Dominant optic atrophy caused by a novel OPA1 splice site mutation (IVS20+1G–>A) associated with intron retention. Ophthalmic Res. 2005;37:214–24. doi:10.1159/000086862.
   PubMed Web of Science ®Google Scholar
• Takano F, Ueda K, Godefrooij DA, Yamagami A, Ishikawa H, Chuman H, Ishikawa H, Ikeda Y, Sakamoto T, Nakamura M. Incidence of Leber hereditary optic neuropathy in 2019 in Japan: a second nationwide questionnaire survey. Orphanet J Rare Dis. 2022;17:319. doi:10.1186/s13023-022-02478-4.
   PubMed Web of Science ®Google Scholar
• Fujiki R, Ikeda M, Yoshida A, Akiko M, Yao Y, Nishimura M, Matsushita K, Ichikawa T, Tanaka T, Morisaki H, et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mole Diagn. 2018;20:572–82.
   PubMed Web of Science ®Google Scholar
• Mizobuchi K, Hayashi T, Yoshitake K, Fujinami K, Tachibana T, Tsunoda K, Iwata T, Nakano T. Novel homozygous CLN3 missense variant in isolated retinal dystrophy: a case report and electron microscopic findings. Mol Genet Genomic Med. 2020;8:e1308. doi:10.1002/mgg3.1308.
   PubMed Web of Science ®Google Scholar
• Mizobuchi K, Hayashi T, Ohira R, Nakano T. Electroretinographic abnormalities in Alport syndrome with a novel COL4A5 truncated variant (p.Try20GlyfsTer19). Doc Ophthalmol. 2023;146:281–91. doi:10.1007/s10633-023-09935-w.
   PubMed Web of Science ®Google Scholar
• Elander J, Ullmark T, Ehrencrona H, Jonson T, Piccinelli P, Samuelsson S, Lowgren K, Falkenius-Schmidt K, Ehinger J, Stenfeldt K, et al. Extended genetic diagnostics for children with profound sensorineural hearing loss by implementing massive parallel sequencing. Diagnostic outcome, family experience and clinical implementation. Int J Pediatr Otorhinolaryngol. 2022;159:111218.
   PubMed Web of Science ®Google Scholar
• Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6. doi:10.1038/nbt.1754.
   PubMed Web of Science ®Google Scholar
• Tadaka S, Hishinuma E, Komaki S, Motoike IN, Kawashima J, Saigusa D, Inoue J, Takayama J, Okamura Y, Aoki Y, et al. jMorp updates in 2020: large enhancement of multi-omics data resources on the general Japanese population. Nucleic Acids Research. 2021;49:D536–D44.
   PubMed Web of Science ®Google Scholar
• Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12:1–11. doi:10.1097/GIM.0b013e3181bf15e3.
   PubMed Web of Science ®Google Scholar
• Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lazaro C, Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet. 2000;9:237–47. doi:10.1093/hmg/9.2.237.
   PubMed Web of Science ®Google Scholar
• Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000; 15: 541–55. doi:10.1002/1098-1004(200006)15.
   PubMed Web of Science ®Google Scholar
• Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lazaro C. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet. 2003;40:e82. doi:10.1136/jmg.40.6.e82.
   PubMed Web of Science ®Google Scholar
• Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017;136:349–76. doi:10.1007/s00439-017-1766-y.
   PubMed Web of Science ®Google Scholar
• Büki G, Zsigmond A, Czakó M, Szalai R, Antal G, Farkas V, Fekete G, Nagy D, Széll M, Tihanyi M, et al. Genotype-phenotype associations in patients with type-1, type-2, and atypical NF1 microdeletions. Front Genet. 2021;12:673025.
   PubMed Web of Science ®Google Scholar
• Melloni G, Eoli M, Cesaretti C, Bianchessi D, Ibba MC, Esposito S, Scuvera G, Morcaldi G, Micheli R, Piozzi E, et al. Risk of optic pathway glioma in neurofibromatosis type 1: no evidence of Genotype–phenotype correlations in a large independent cohort. Cancers Basel. 2019;11:1838.
   PubMed Web of Science ®Google Scholar
• Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS. 2010;14:511–7. doi:10.1016/j.jaapos.2010.08.014.
   PubMed Web of Science ®Google Scholar
• Topcu-Yilmaz P, Kasim B, Kiratli H. Investigation of retinal nerve fiber layer thickness in patients with neurofibromatosis-1. Jpn J Ophthalmol. 2014;58:172–6. doi:10.1007/s10384-014-0308-6.
   PubMed Web of Science ®Google Scholar
• Parrozzani R, Clementi M, Kotsafti O, Miglionico G, Trevisson E, Orlando G, Pilotto E, Midena E. Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Visual Sci. 2013;54:8112–8. doi:10.1167/iovs.13-13093.
   PubMed Web of Science ®Google Scholar
• Parrozzani R, Miglionico G, Leonardi F, Pulze S, Trevisson E, Clementi M, Opocher E, Licata V, Viscardi E, Pilotto E, et al. Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma. Acta Ophthalmol. 2018;96:e1004–e9.
   PubMed Web of Science ®Google Scholar
• Abdolrahimzadeh S, Felli L, Plateroti AM, Perdicchi A, Contestabile MT, Recupero SM. Spectral domain optical coherence tomography evidence of retinal nerve fiber layer and ganglion cell loss in adult patients with neurofibromatosis type 1. Retina. 2016;36:75–81. doi:10.1097/IAE.0000000000000650.
   PubMed Web of Science ®Google Scholar